A randomized study published in The Lancet tested ScreenPoint Medical’s Transpara Detection AI in breast‑cancer screening for over 100,000 women and found a 12% reduction in interval cancers versus standard mammography. The trial demonstrates that AI detection software can shift screening performance by identifying cancers missed at initial reads, potentially lowering downstream morbidity. The result will prompt screening programs and payers to consider AI augmentation, though deployment questions remain—workflow integration, radiologist acceptance, external validation across populations, and regulatory acceptance for screening use.